Tendinopathies Associated with Statin Therapy in Patients with Dyslipidemia: Case Study

Main Article Content

Denisse Eugenia Aguilar Domínguez
Erika Palacios Rosas
Jorge Luis León Álvarez

Abstract

Statins are considered the initial and first-line treatment in cardiovascular and atherosclerotic diseases, characterized by inhibiting HMG-CoA reductase. Some adverse effects associated with these drugs are injuries to the tendon structure including tenosynovitis, tendon and tendon rupture.


The aim of this article is to evaluate the tendon structure by musculoskeletal ultrasound and to raise the question of whether chronic statin consumption in this patient with dyslipidemia is related to the appearance of tendinopathies.


Methodology A cross-sectional descriptive observational study was carried out, focused on the evaluation of the incidence of tendinopathies in patients who have been using statins chronically. A case study approach was used, analysing in detail a female patient selected according to the established inclusion and exclusion criteria.


The sample consisted of a patient who met the inclusion criteria: age between 45-60 years, chronic use of statins for more than 12 months, presentation of symptoms suggestive of tendinopathy.


Patients with a history of musculoskeletal diseases prior to the start of treatment were excluded, and anyone with arthritis, chronic septic inflammatory processes, athletes, young patients, and those who did not want to participate in the study and did not agree to give informed consent were excluded.


For data collection, 7 patients were selected, of which 1 only met the inclusion and acceptance criteria for the study, a clinical history was taken with exhaustive clinical evaluations of the selected patients, focused on the identification of tendinopathy symptoms and other possible risk factors, at the end a musculoskeletal ultrasound was carried out where possible tendon injuries were identified and characterized.  evaluating tendon structure and its relationship to statin use. This methodology provides a detailed and structured approach to conducting research on the incidence of tendinopathies associated with statin use.


Results During the clinical evaluation of this patient, symptoms associated with tendinopathy of the long portion of the biceps brachii on the right side were identified. The results of the musculoskeletal ultrasound confirmed the alterations in the structure of the tendon, finding tenosynovitis, significant peritendinous effusion and microruptures of the long portion of the biceps brachii not only on the affected side,  but also on the contralateral side, which was asymptomatic for tendon pathology. In addition, not only was the biceps tendon modified, micro ruptures in the supraspinatus tendon and subacromial bursitis were observed. This patient had been taking atorvastatin 20mg every 24 hours in the mornings for 9 years and was not attributed with any mechanism of overuse injury that triggered multiple tendinopathies at the rotator cuff level.

Article Details

How to Cite
Denisse Eugenia Aguilar Domínguez, Erika Palacios Rosas, & Jorge Luis León Álvarez. (2024). Tendinopathies Associated with Statin Therapy in Patients with Dyslipidemia: Case Study. International Journal of Medical Science and Clinical Research Studies, 4(04), 699–703. https://doi.org/10.47191/ijmscrs/v4-i04-16
Section
Articles

References

I. Bard, H. (2012). Tendinopathies: etiopathogenesis, diagnosis and treatment. CME Musculoskeletal System; 45(3):1-20 [Article E – 14-469]. Retrieved from:

https://sci hub.se/https://doi.org/10.1016/S1286-935X(12)62764-6.

II. Bolon, B. (2017). Mini-Review: Toxic Tendinopathy. Toxicologic Pathology, 45(7), 834-837. doi: 10.1177/0192623317711614. https://journals.sagepub.com/doi/10.1177/0192623317711614?url_ver=Z39.88- 2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed

III. Cook, J., Eboni, R., Purdam, C., & Ortega-Cebrian, S. (2017). The Continuum of Tendon Pathology: Current Concept and Clinical Implications. Apunts Med Esport, 52, 63,64,65. doi: doi.org/10.1016/j.apunts.2017.05.002. Retrieved from: https://www.apunts.org/en-pdf X0213371717613161

IV. Delgado, L., Alvarez, B., De la Cruz, J., & Ramirez S, A. (2012). Statin Rhabdomyolysis: A Fatal Case Report and Review of the Literature. Mexican Journal of Cardiology, 23(1), 27-30. Retrieved from https://www.medigraphic.com/pdfs/cardio/h-2012/h121f.pdf

V. Eliasson, P., Dietrich-Zagonel, F., Lundin, A., Aspenberg, P., Wolk, A., & Michaëlsson,

VI. K. (2019). Statin treatment increases the clinical risk of tendinopathy through matrix

VII. metalloproteinase release – a cohort study design combined with an experimental study. Scientific Reports, 9(1). doi: 10.1038/s41598-019-53238-7. https://pubmed.ncbi.nlm.nih.gov/31784541/

VIII. Goodman & Gilman 1906-, Blengio Pinto, J., Rivera Muñoz, B., & Girolamo, G. (2007). The pharmacological basis of therapeutics (p. 780). Mexico: McGraw-Hill Interamericana.

IX. Guerra FR, V. (2013). Statin Therapy and Tendon Disorders. Journal Of Glycomics & Lipidomics, 03(01). doi: 10.4172/2153-0637.1000e115. Retrieved from: Guillen, J.F. (2005). Terminology and classification of tendinopathies. Spanish Society of Sports Medicine. Retrieved from:

http://www.femede.es

X. Jeong, C., Kim, S., Shim, K., Kim, H., Song, M., Park, K., & Song, H. (2018). Exploring the In Vivo Anti-Inflammatory Actions of Simvastatin-Loaded Porous Microspheres on Inflamed Tenocytes in a Collagenase-Induced Animal Model of Achilles Tendinitis. International Journal Of Molecular Sciences, 19(3), 820. doi: 10.3390/ijms19030820.

Hatps://vv.nakbi.nalam.nih.gov/pmc/articles/pmc5877681/pdf/ijms-19-00820.pdf

XI. Kaleağasıoğlu, F., Olcay, E., & Olgaç, V. (2015). Statin-induced calcific Achilles tendinopathy in rats: comparison of biomechanical and histopathological effects of simvastatin, atorvastatin and rosuvastatin. Knee Surgery, Sports Traumatology, Arthroscopy, 25(6), 1884-1891. doi: 10.1007/s00167-015-3728-z. https://pubmed.ncbi.nlm.nih.gov/26275370/

XII. Knobloch, K. (2016). Drug-Induced Tendon Disorders. Metabolic Influences on Risk For Tendon Disorders, 229-238. doi: 10.1007/978-3-319-33943-6_22.

XIII. Liao, X., Falcon, N., Mohammed, A., Paterson, Y., Mayes, A., Guest, D., & Saeed, A. (2020). Synthesis and Formulation of Four-Arm PolyDMAEA-siRNA Polyplex for Transient Downregulation of Collagen Type III Gene Expression in TGF-β1 Stimulated Tenocyte Culture. ACS Omega, 5(3), 1496-1505. doi: 10.1021/acsomega.9b03216 https://pubs.acs.org/doi/10.1021/acsomega.9b03216

XIV. Mennickent, S. (2008). Pleiotropic effects of statins. Medical journal of chile. (136), 775-782. https://scielo.conicyt.cl/pdf/rmc/v136n6/art14.pdf

XV. Muhammad, Z., Ahmad, T., & Baloch, N. (2019). Can alternate-day Statin regimen minimize its adverse effects on muscle and tendon? A systematic review. J Pak Med Assoc, 69(07), 1006-1008. Retrieved from https://jpma.org.pk/PdfDownload/9237.

XVI. Ramos, P. (2015). From the concept of high-potency statins to the extralipidic effects of statins. Spanish Journal of Cardiology Supplements, 15, 22-27. doi: 10.1016/s1131-3587(15)70121-4. Retrieved from: https://www.revespcardiol.org/es of-the-statin-concept-high-potency-article-S1131358715701214

XVII. Soslowsky, L., & Fryhofer, G. (2016). Tendon Homeostasis in Hypercholesterolemia. Metabolic Influences On Risk For Tendon Disorders, 151- 165. doi: 10.1007/978-3-319-33943-6_14. Recuperado de:

https://link.springer.com/article/10.1007%2Fs11926-017-0704-2

XVIII. Tsai, W., Yu, T., Lin, L., Cheng, M., Chen, C., & Pang, J. (2015). Prevention of Simvastatin Induced Inhibition of Tendon Cell Proliferation and Cell Cycle Progression by Geranylgeranyl Pyrophosphate. Toxicological Sciences, 149(2), 326-334. doi: 10.1093/toxsci/kfv239. Recuperado de:

https://academic.oup.com/toxsci/article/149/2/326/2461515